1. Home
  2. INCR vs GLTO Comparison

INCR vs GLTO Comparison

Compare INCR & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercure Ltd.

INCR

Intercure Ltd.

HOLD

Current Price

$0.85

Market Cap

50.4M

Sector

Health Care

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$29.77

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INCR
GLTO
Founded
1994
2011
Country
Israel
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.4M
54.5M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
INCR
GLTO
Price
$0.85
$29.77
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$43.67
AVG Volume (30 Days)
54.1K
303.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$69.54
N/A
Revenue Next Year
$41.75
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$2.01
52 Week High
$1.77
$38.33

Technical Indicators

Market Signals
Indicator
INCR
GLTO
Relative Strength Index (RSI) 40.76 56.13
Support Level $0.76 $3.32
Resistance Level $0.98 $32.63
Average True Range (ATR) 0.06 2.98
MACD 0.00 0.27
Stochastic Oscillator 38.70 71.50

Price Performance

Historical Comparison
INCR
GLTO

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: